表紙
市場調査レポート

幹細胞技術:米国・欧州・イスラエル・アジア市場の分析と主要企業 2016-2026年

Pharma Leader Series - Top Stem Cell Companies Report 2016-2026: Market Analysis and Leading Players in the United States, Europe, Israel and Asia

発行 Visiongain Ltd 商品コード 297620
出版日 ページ情報 英文 216 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=137.27円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
幹細胞技術:米国・欧州・イスラエル・アジア市場の分析と主要企業 2016-2026年 Pharma Leader Series - Top Stem Cell Companies Report 2016-2026: Market Analysis and Leading Players in the United States, Europe, Israel and Asia
出版日: 2016年04月06日 ページ情報: 英文 216 Pages
概要

世界の幹細胞市場における総収益は2020年に178億米ドルに達し、技術進歩により、2026年まで高成長が見込まれています。

当レポートでは、世界の幹細胞市場における主要企業25社のプロファイルを地域ごとに提供しており、今後の市場予測、幹細胞産業・市場を形成する技術の進歩と可能性、および調査インタビューなどをまとめ、お届けいたします。

第1章 調査概要

第2章 世界の幹細胞技術・アプリケーション市場:イントロダクション

  • 幹細胞技術・アプリケーション市場
  • 世界の幹細胞技術・アプリケーション市場予測
  • 治療の可能性、薬剤スクリーニングおよび新興市場による急成長
  • 幹細胞技術・アプリケーション市場の促進因子・抑制因子

第3章 米国の主要な幹細胞技術企業

  • 米国における幹細胞の規制環境
  • Osiris Therapeutics
  • Caladrius Biosciences (前 Neostem)
  • Orthofix
  • NuVasive
  • AlloSource
  • RTI Surgical
  • Vericel Corporation (前 Aastrom Biosciences)
  • U.S. Stem Cell Inc (前 Bioheart)
  • Neuralstem
  • Astellas/Ocata Therapeutics (前 Advanced Cell Technology)
  • Athersys
  • 臍帯血幹細胞の認可:処置から製品へ

第4章 アジア太平洋地域の主要な幹細胞技術企業

  • 韓国:MSC療法の商業化へ急速に移行 - しかし十分な注意を払っているか?
  • インド:新興の幹細胞産業
  • 日本:hESC研究において他のアジア諸国よりも不活発だが、推進へ向けた新たな経路を実行
  • 中国:幹細胞研究に対する進歩的な法律を厳しく取り締まるための措置を取る
  • オーストラリアは厳しく規制する環境が無い
  • Mesoblast Ltd:広範な製品パイプラインを有するオーストラリア企業
  • Reliance Life Sciences
  • Anterogen
  • Pharmicell
  • MEDIPOST
  • Stempeutics

第5章 欧州の主要な幹細胞技術企業

  • 欧州における規制
  • 英国は欧州の幹細胞R&Dをリード
  • TiGenix:特許技術プラットフォームおよび3つの幹細胞製品を開発中
  • Celyad (前 Cardio3 BioSciences)
  • Apceth
  • ReNeuron

第6章 イスラエルの主要な幹細胞技術企業

  • イスラエル:幹細胞研究における強いプレゼンス
  • Gamida Cell
  • Cell Cure Neurosciences
  • Pluristem Therapeutics
  • BrainStorm Cell Therapeutics

第7章 幹細胞技術市場の定性分析

  • SWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
  • 幹細胞技術市場のSTEP分析
  • 社会的要因
  • 技術的要因
  • 経済的要因
  • 政治的要因

第8章 調査インタビュー

第9章 結論

  • 米国は幹細胞研究の分野をリード
  • 市場は資本化の状態にあり、投資・提携は不可欠
  • 産業は革新的な新発見を続ける
  • 産業には克服すべき多くの障壁が存在
  • 競争が激化する見込み
  • 幹細胞技術市場の将来

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0107

Leading Stem Cell Companies - Discover What Their Futures Hold, Benefiting Your Reputation for Commercial Insight

Who are the leading stem cell developers and producers? And what are their sales outlooks? Visiongain's updated report shows you their activities and potentials from 2016. There you discover therapies, results, trends in research and development, opportunities and revenue forecasts.

That way you explore data and discussions on cellular technologies transforming human medicine. Our study analyses 25 leading companies in the US, Europe, Israel and Asia-Pacific. There you hear how stem cell producers can progress and gain. Discover their potentials and see what the future holds.

Please read on, then, to scan those organisations and find what revenue that fast-growing and potentially large market could generate in future. See what is possible.

Forecasts and other data to benefit your authority on stem cell biotechnology

In our study you find profiles of 25 prominent stem cell companies and analyses of their industry. You explore sales results, R&D and revenue forecasting. Explore, from 2016, those firms' capabilities, portfolios and commercial prospects.

In our updated report you gain 55 tables, 24 charts and two interviews with that industry. You see our discussions with authorities from Mesoblast and Gamida Cell.

With our study you could help your research, analyses and decisions, also saving time. And see how you could benefit your reputation for commercial insight.

Stay ahead, then, for knowledge on that vast, rising industry. The following sections explain how our new investigation benefits your work.

image1

United States (US) - assess leading organisations, seeing what is possible

First our study gives you discussions, analyses and commercial outlooks for 11 US-based stem cell companies:

  • Osiris Therapeutics
  • Caladrius Biosciences
  • Orthofix
  • NuVasive
  • AlloSource
  • RTI Surgical
  • Vericel Corporation
  • U.S. Stem Cell, Inc.
  • Neuralstem
  • Astellas/Ocata Therapeutics
  • Athersys

image2

There you hear what the future holds for those cellular biology companies, including regulations, research trends and some revenue predictions.

Our study then analyses Asian organisations, explaining that region's potential.

Stem cell specialists based in the Asia Pacific region - what developments possible?

You also discover commercial outlooks for six top researchers, developers and producers of stem cells in the Asia Pacific region:

  • Mesoblast
  • Reliance Life Sciences
  • Anterogen
  • Pharmicell
  • MEDIPOST
  • Stempeutics.

Our analyses show possibilities for advancing technology and raising business performance, assessing where future sales expansion is possible. Explore regulations and see how companies progress, assessing revenue potentials.

The report then analyses Europe and Israel, showing those countries' activities and potentials.

Companies based in Europe and Israel - what successes can they achieve?

Our analysis also shows you progress and prospects for eight European and Israeli companies:

  • TiGenix
  • Celyad
  • Apceth
  • ReNeuron
  • Gamida Cell
  • Cell Cure Neurosciences
  • Pluristem Therapeutics
  • BrainStorm Cell Therapeutics.

Many opportunities arise in that industry, with high, expanding revenues possible from this decade. In our study you also explore clinical testing and plans for launching products.

Predictions for the worldwide stem cells market - see that industry's sales potential

Our report also forecasts sales to 2026 for the overall world stem cells industry. There you find revenues reaching $17.8bn in 2020, with high growth to 2026.

In our study you also gain revenue forecasting to 2026 for these products:

  • Trinity Elite and Trinity Evolution
  • Osteocel Plus
  • MSC-100-IV
  • CardioRel
  • Hearticellgram-AMI
  • Cartistem.

See there how applications of stem cells can perform. Find, from 2016, where those organisations can generate high sales. That industry holds vast potential.

With our report you assess how stem cell companies can compete and succeed. See what their future holds and how you can gain.

Technologies and issues shaping that industry and market - what is happening?

Our study explains stem cell technologies and forces influencing that industry and market. There you explore developments and forces, including these:

  • Sales potentials of leading stem cell therapies to 2026 - see what is possible
  • Embryonic stem cells - potentials in tissue repair and regenerative medicine
  • Autologous and allogeneic agents, including T cell therapy
  • Advances in treating eye disorders, e.g. age-related macular degeneration (AMD)
  • Novel treatments for cancer and other applications - e.g. diabetes and bone re-growth - including progress of clinical trials and product launches.

With that work you assess these influences, too, among others:

  • Regulations for that research and its applications - see what countries do
  • Umbilical cord blood - applications and approvals for that tissue and cell banking
  • Mergers, acquisitions, alliances and venture capital - explore what shapes that industry and affects its future
  • Non-therapeutic pharma applications - screening and toxicity studies in drug development.

In our survey you also find interviews with two companies - Mesoblast and Gamida Cell. There gain information to help you stay ahead in knowledge on challenges, progress, potentials and future trends.

See what is possible, then, for that cell-based biotechnology and explore what its future holds.

Ways Pharma Leader Series: Top Stem Cell Companies Report 2016-2026 helps you

In particular, our independent analysis gives you this knowledge to benefit your work:

  • Profiles of 25 leading stem cell companies in North America, Europe, Israel and Asia - assess products, R&D, results, strategies, alliances and sales outlooks
  • Revenue forecasting to 2026 for that overall world market - discover potential sales, exploring those technologies' commercial prospects
  • Forecast revenues to 2026 for leading stem cell products - see how top companies' technologies can compete and succeed
  • Opportunities, competition and demands - explore what affects companies, finding what influences sales and shapes organisations' futures
  • Interviews with companies in that industry - find what participants say and do, helping you stay ahead in knowledge and benefit your influence.

That report, by visiongain's in-house analysts in the UK, gives knowledge to benefit your work. Its purpose is to help you save time and avoid struggles to find information. You gain analysis to benefit your plans, decisions and presentations.

Data found nowhere else, benefiting your research, analyses and proposals

Our report gives independent analysis. There you get competitive intelligence found only in that work, assessing commercial potentials. Explore what the future holds.

With our analysis you are less likely to fall behind in information or miss opportunity. There see how you could save time and effort. So benefit your plans, decisions and influence now, helping you gain advantages and succeed.

By trying our latest study on stem cells, you explore trends, R&D and sales predictions. You assess the present and future of companies. Avoid missing out on data and discussions to help you stay ahead.

Table of Contents

1. Report Overview

  • 1.1 Global Stem Cell Technology Market Segmentation
  • 1.2 Top Stem Cell Technology Companies Globally: An Overview
  • 1.3 How This Report Delivers
  • 1.4 Questions Answered by This Analytical Study
  • 1.5 Who is This Report For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. Introduction to the Global Stem Cell Technology and Applications Market 2014 to 2026

  • 2.1 The Stem Cells Technologies and Applications Market in 2015
  • 2.2 Global Stem Cell Technology and Applications Market Forecast 2016-2026
  • 2.3 Fast Growth Due to Therapeutic Potential, Drug Screening and Emerging National Markets
  • 2.4 Drivers and Restraints for the Stem Cell Technology and Applications Market, 2016-2026

3. Leading US Stem Cell Technology Companies

  • 3.1 The Stem Cell Regulatory Environment in the US
    • 3.1.1 Embryonic Stem Cell Research in the US is Still Controversial
  • 3.2 Osiris Therapeutics
    • 3.2.1 Grafix: Additional Clinical Trials to Gain Advantage
      • 3.2.1.1 Is Grafix Really a 'Stem Cell Product'?
    • 3.2.2 Bio4: Further Rebranding of a Stem Cell Product for Regeneration of Bone Tissue
    • 3.2.3 Cartiform - Launched to Address a Potential $500m Market
      • 3.2.3.1 Partnership with Arthrex for Development of Cartiform and Further Pipeline Expansion
    • 3.2.4 Osiris Therapeutics Stem Cell Revenue Forecast 2015-2026
    • 3.2.5 Osiris Therapeutics: Optimistic Outlook for that Leading Stem Cell Company
  • 3.3 Caladrius Biosciences (formerly Neostem)
    • 3.3.1 Growth Through Acquisitions - Including PCT, Amorcyte, Athelos and California Stem Cell Inc.
    • 3.3.2 Focus Shifted to CLBS12, CLBS10 Is No Longer the Lead Candidates
    • 3.3.3 VSEL Technology: Potential to Treat Ocular Diseases and Chronic Wounds?
    • 3.3.4 Caladrius Biosciences Revenues 2012-2015
    • 3.3.5 Caladrius Biosciences Outlook in Summary: Current Stem Cell Therapy Development is Not Active
  • 3.4 Orthofix
    • 3.4.1 Trinity Evolution and Trinity Elite - Over 135,000 Procedures to Date
      • 3.4.1.1 Positive Results from New Trial in Foot and Ankle Procedures
      • 3.4.1.2 Trinity Elite and Trinity Evolution: Revenue Forecast 2015-2026
    • 3.4.2 Orthofix Outlook in Summary: High Revenues from Trinity Products but Will Have to Demonstrate Efficacy
  • 3.5 NuVasive
    • 3.5.1 Osteocel to Osteocel Plus: Changes and Challenges
      • 3.5.1.1 Osteocel Plus: The Leading Stem Cell Orthobiologic
      • 3.5.1.2 Osteocel Plus: Is it Better than Autograft?
      • 3.5.1.3 Developments at NuVasive: Acquisitions
      • 3.5.1.4 Osteocel Plus: Revenue Forecast 2015-2026
    • 3.5.2 NuVasive Outlook in Summary: Osteocel Plus Revenues Will Continue to Grow, Although will Face Increased Competition in Coming Years
  • 3.6 AlloSource: Non-Profit which Markets AlloStem and Processes Osteocel for NuVasive
    • 3.6.1 AlloStem: Stem Cell Bone Growth Substitute
  • 3.7 RTI Surgical
    • 3.7.1 Map3: RTI Surgical is Competing with Established Players like NuVasive and Orthofix
  • 3.8 Vericel Corporation (formerly Aastrom Biosciences)
    • 3.8.1 Leading Stem Cell Therapy Candidate Ixmyelocel-T
      • 3.8.1.1 Mechanism of Vericel's Stem Cell Treatment Ixmyelocel-T
    • 3.8.2 Investigation of Ixmyelocel-T: DCM Is its Leading Indication
    • 3.8.3 Vericel Focusing on Dilated Cardiomyopathy (DCM) but CLI Trials Are Discontinued
    • 3.8.4 Acquisition of New Products: Carticel, Epicel and MACI
    • 3.8.5 Vericel Corporation Revenue 2011-2014
    • 3.8.6 Vericel Corporation Outlook in Summary: Expectations All on One Treatment
  • 3.9 U.S. Stem Cell Inc (formerly Bioheart)
    • 3.9.1 MyoCell: Autologous 'Muscle Stem Cell' Therapy
      • 3.9.1.1 MyoCell: Undergoing Phase 2/3 MARVEL Trial But Needs Funding
      • 3.9.1.2 MyoCell: MIRROR Phase 3 Development Halted
    • 3.9.2 MyoCell SDF-1: Improved Version of MyoCell
      • 3.9.2.1 MyoCell SDF-1 Phase 1 Trial (REGEN) Trial On Hold Also
    • 3.9.3 Adipocell Halted for CHF, but in Phase 1/2 for CLI with Future Aims to Expand to Rheumatoid Arthritis Treatment
      • 3.9.3.1 Adipocell: DDD, COPD and Dry Macular Degeneration Investigations and Expansion to India for Clinical Trials
    • 3.9.4 Pipeline Development for An As Yet Unnamed Neurological Treatment
    • 3.9.5 U.S. Stem Cell Inc. Revenues 2011-2015
    • 3.9.6 U.S. Stem Cell Inc. Outlook in Summary: Promising Candidates With Halted Development
  • 3.10 Neuralstem
    • 3.10.1 NSI-566 Completed Phase 2 for ALS in Q1 2015 With Further Studies Anticipated in 2016
    • 3.10.2 NSI-566 for Chronic Spinal Cord Injury: Phase 1 Nearing Completion with Phase 1/2 for Acute Spinal Cord Injury Beginning in Korea
    • 3.10.3 NSI-566 for Ischaemic Stroke: Phase 1/2 Trials Underway in China
    • 3.10.4 Neuralstem: Preclinical Investigation for 11 Other Indications and NSI-189 in Phase 2 Trials
    • 3.10.5 Neuralstem Revenues 2011-2014
    • 3.10.6 Neuralstem Outlook in Summary: Aiming to Treat a Wide Range of Conditions - Potential Revenues are Huge
  • 3.11 Astellas/Ocata Therapeutics (formerly Advanced Cell Technology)
    • 3.11.1 Broad Intellectual Property Portfolio and Funding Issues Solved
    • 3.11.2 MA09-hRPE in Two Phase 1/2 Trials for Stargardt's Macular Degeneration
      • 3.11.2.1 Possible Early Signals of Efficacy
    • 3.11.3 MA09-hRPE: Phase 2 in Dry Age Related Macular Degeneration and Phase 1/2 for Myopic Macular Degeneration
    • 3.11.4 Ocata Therapeutics Revenues, 2011-2014
    • 3.11.5 Astellas/Ocata Therapeutics Outlook in Summary: Strengthened Through its Parent Company
  • 3.12 Athersys
    • 3.12.1 Leading Product: MultiStem Demonstrates Positive Results in Phase 2 Trials for Ischaemic Stroke
    • 3.12.2 MultiStem Is Also In Development for Other Indications Although Not All Have Been Successful
    • 3.12.3 Plans for MultiStem to Enter the Japanese Market
    • 3.12.4 Athersys Revenues
    • 3.12.5 Athersys Outlook in Summary: Strong Potential of MultiStem
  • 3.13 Cord Blood Stem Cells Approvals: Procedures to Products
    • 3.13.1 Hemacord by New York Blood Center
    • 3.13.2 HPC, Cord Blood by ClinImmune and University of Colorado Cord Blood Bank
    • 3.13.3 Ducord by Duke University School of Medicine
    • 3.13.4 Allocord by SSM Cardinal Glennon Children's Medical Center
    • 3.13.5 HPC, Cord Blood BLA 125432 by LifeSouth Community Blood Centers
    • 3.13.6 HPC Cord Blood by Bloodworks Northwest

4. Leading Asia-Pacific Stem Cell Technology Companies

  • 4.1 South Korea: Moving Rapidly to Commercialisation for MSC Therapies - but is it Exercising Enough Caution?
  • 4.2 India: An Emerging Stem Cell Industry
  • 4.3 Japan: Has Been Less Active than other Asian Countries in hESC Research But Has Implemented a New Pathway to Encourage Growth
  • 4.4 China: Taking Measures to Tighten Up Liberal Stem Cell Research Laws
  • 4.5 Australia Unrestrictive Regulatory Environment
  • 4.6 Mesoblast Ltd: Australian Company with Extensive Product Pipeline
    • 4.6.1 Mesoblast's Strategic Partnering and Acquisitions
    • 4.6.2 Mesoblast's Broad Pipeline: MSC-100-IV Is the Lead Candidate
    • 4.6.3 MSC-100-IV (formerly Prochymal): World's First Approved Stem Cell Drug Outside of South Korea- Currently Has Limited Market Access
      • 4.6.3.1 Mesoblast Also Evaluating MSC-100-IV for Treatment of Crohn's Disease
      • 4.6.3.2 MSC-100-IV: Revenue Forecast, 2016-2026
    • 4.6.4 Mesoblast Evaluating MPCs for Treatment of Diabetes in Phase 2
    • 4.6.5 Mesoblast Evaluating MPCs for Treatment of Rheumatoid Arthritis in Phase 2
    • 4.6.6 MPC-150-IM in Phase 3 for Chronic Heart Failure
    • 4.6.7 Phase 2 Trial of MPCs in Acute Myocardial Infarction with MPC-25-IC
    • 4.6.8 Phase 3 Trials of MPCs in Intervertebral Disc Repair and Spinal Fusion
    • 4.6.9 Trials Involving Umbilical Cord Blood Cells Expanded with MPCs in Haematological Malignancies
    • 4.6.10 Phase 2 in Wet AMD, Preclinical in Neurology
    • 4.6.11 Mesoblast Revenue 2012-2015
    • 4.6.12 Mesoblast Outlook in Summary: Large and Diversified Development Pipeline Supports a Leading Company
  • 4.7 Reliance Life Sciences
    • 4.7.1 CardioRel - Available in the Indian Market Only
      • 4.7.1.1 CardioRel: Revenue Forecast 2015-2026
    • 4.7.2 ReliNethra- The First Stem Cell Therapy in India
    • 4.7.3 ReliNethra C and A Possible Neurological Disorder Treatment, NeuroRel
    • 4.7.4 Cord Blood Repository for Stem Cell Storage
    • 4.7.5 Reliance Life Sciences Outlook in Summary: More Diversification is Needed
  • 4.8 Anterogen
    • 4.8.1 Cupistem is the World's First Approved Stem Cell Product Derived From Adipose Tissue
    • 4.8.2 Queencell and Adipocell: Stromal Vascular Fraction Containing Autologous MSCs and Depressed Scar Treatment
    • 4.8.3 Anterogen's Expanding Pipeline
    • 4.8.4 Anterogen Outlook in Summary: A Strong Player in the Korean Market
  • 4.9 Pharmicell
    • 4.9.1 Hearticellgram-AMI is One of the First Approved Cardiovascular Stem Cell Treatments
      • 4.9.1.1 Hearticellgram-AMI May Not Be Easily Approved Outside of South Korea
      • 4.9.1.2 Hearticellgram-AMI Revenue Forecast 2015-2026
    • 4.9.2 Cerecellgram Has Reached Phase 3 For the Treatment of Strokes and Phase 2/3 For Spinal Cord Injuries
    • 4.9.3 Immunocellgram for Cancers and Lungcellgram for Pulmonary Fibrosis Are Both In Preclinical Development
    • 4.9.4 Other Phase 1 Treatments for Erectile Dysfunction and Multiple System Atrophy
    • 4.9.5 Livercellgram for Hepatic Failure Treatment Has Completed Phase 2
    • 4.9.6 Pharmicell Outlook in Summary: Quick to Market With a Large Pipeline But May Have Difficulty With Regional Expansion
  • 4.10 MEDIPOST
    • 4.10.1 Cartistem is the World's First Approved Allogeneic Stem Cell Drug Treatment
    • 4.10.2 Cartistem's Development: Phase 3 Updates and Expansion
    • 4.10.3 Cartistem Revenue Forecast 2015-2026
    • 4.10.4 Neurostem Has Reached Phase 1/2a
    • 4.10.5 Pneumostem and Promostem: Lung Disease Stem Cell Treatment and Haematopoietic Transplantation Therapy
    • 4.10.6 MEDIPOST Outlook in Summary: One Stem Cell Therapy Launched, Plans to Expand, and the Largest Cord Blood Repository in South Korea
  • 4.11 Stempeutics
    • 4.11.1 Stempeucel Has Reached Phase 2 For Various Indications
    • 4.11.2 Stempeucel for Various Other Indications
    • 4.11.3 Alliance with Cipla
    • 4.11.4 Developments at Stempeutics: Patent Approvals and Developments in the European Marketplace
    • 4.11.5 Stempeutics Outlook in Summary: Using Stempeucel to Treat a Range of Disorders

5. Leading European Stem Cell Technology Companies

  • 5.1 Regulation in Europe
  • 5.2 UK Leads in European Stem Cell R&D
  • 5.3 TiGenix: Proprietary Technology Platform and Three Stem Cell Products in Development
    • 5.3.1 ChondroCelect Already on the Market
    • 5.3.2 eASC Technology Platform
    • 5.3.3 Favourable Data Released for Cx601's European Phase 3 Trial
      • 5.3.3.1 The Road to Approval for Cx601 in Europe and the US
      • 5.3.3.2 Cx601: TiGenix Partners with Lonza and Plans to Launch in the US and Europe
    • 5.3.4 Cx611: Phase 2 for Rheumatoid Arthritis Delayed and Phase 1/2 for Severe Sepsis Planned
    • 5.3.5 Cx621 - Positive Results from Phase 1 But Development is Halted
    • 5.3.6 TiGenix Outlook in Summary: Cx601 Reaching End of Development and Represents the Company's Greatest Strength
  • 5.4 Celyad (formerly Cardio3 BioSciences)
    • 5.4.1 Celyad's Proprietary Cardiopoiesis Technology Platform - Can be Applied to Various Stem Cell Sources
    • 5.4.2 C-Cure: Stem Cell Therapy for the Treatment of Heart Failure
      • 5.4.2.1 C-Cure: Two Phase 3 Trials Underway
    • 5.4.3 New Agreements: Possible Extension of C-Cure Into the Asian Market and Customised Automated Manufacturing
    • 5.4.4 Celyad Outlook in Summary: Targeting a Therapeutic Area with High Unmet Need
  • 5.5 Apceth
    • 5.5.1 Proprietary Technology Platform Delivers Therapeutic Genes Directly to the Target
    • 5.5.2 Agenmestencel-T for the Treatment of GI-tract Adenocarcinoma
    • 5.5.3 Alecmestencel-T for the Treatment of PAOD/CLI
    • 5.5.4 Alecmestencel-L for the Treatment of GvHD
    • 5.5.5 Technology Licensing Agreement With Cynata Therapeutics
    • 5.5.6 Apceth Outlook in Summary: A Variety of Industry Firsts and Positive Outlook, Although Pipeline is in Early Stages
  • 5.6 ReNeuron
    • 5.6.1 CTX Neural Cell Line: Provides Technical and Competitive Advantages
      • 5.6.1.1 CTX for Stroke: Promising Results Lead to Next Stage
      • 5.6.1.2 CTX for Stroke: Phase 2 Study Developments and a Long-Term Observational Study
      • 5.6.1.3 CTX for Critical Limb Ischaemia: Phase 1 Will be Completed This Year
    • 5.6.2 hRPCs for the Treatment of Retinitis Pigmentosa Has Reached Phase 1/2 and is ReNeuron's First US Clinical Trial
    • 5.6.3 Exosome Technology Platform in Preclinical Trials with Potential in Oncology Treatment
    • 5.6.4 Non-therapeutic Products: ReNcell VM and ReNcell CX, Licensed to Merck Millipore
    • 5.6.5 Recent Developments in the Company: Investment and Collaboration
    • 5.6.6 ReNeuron Revenue, 2012-2015
    • 5.6.7 ReNeuron Outlook in Summary: Underlying Platform a Major Strength and Source of Competitive Advantage

6. Leading Israeli Stem Cell Technology Companies

  • 6.1 Israel: A Strong Presence in Stem Cell Research
  • 6.2 Gamida Cell
    • 6.2.1 Novartis Not to Buy Gamida Cell and Invests Further Instead
    • 6.2.2 NAM Technology Platform
    • 6.2.3 Copper Chelator Based Technology
    • 6.2.4 StemEx: Halted Development
    • 6.2.5 NiCord - Aiming for a "Paradigm Shift" in Treatment Practice, Receives Orphan Drug Designation
    • 6.2.6 CordIn: New Product in the Pipeline
    • 6.2.7 Gamida Cell Outlook in Summary: Strong Support and Potential
  • 6.3 Cell Cure Neurosciences
    • 6.3.1 Technological Platform to Produce Retinal Pigmented Epithelial Cells for the Treatment of AMD
    • 6.3.2 OpRegen and OpRegen Plus: Product Candidates for Dry AMD
    • 6.3.3 Exclusive Licence Agreement with Teva for OpRegen and Possibly OpRegen Plus
    • 6.3.4 Cell Cure Neurosciences Outlook in Summary: Focusing on Only Retinal Therapies with a Small Pipeline
  • 6.4 Pluristem Therapeutics
    • 6.4.1 PLX Cells: Secretes Therapeutic Proteins in Damaged Tissues
    • 6.4.2 PLX-PAD is in Phase 2 for Intermittent Claudication and Prepares to Initiate Phase 2 for CLI With Further Expansions Planned
    • 6.4.3 PLX-PAD for Injured Gluteal Muscle in Phase 1/2 and for PAH in Phase 1
    • 6.4.4 PLX-R18 for ARS in Preclinical Development
    • 6.4.5 Agreements and Partnerships: Change for Pluristem
    • 6.4.6 Pluristem Therapeutics Revenue, 2012-2015
    • 6.4.7 Pluristem Therapeutics Outlook in Summary: Proprietary Technology and PLX-PAD for Multiple Indications
  • 6.5 BrainStorm Cell Therapeutics
    • 6.5.1 A Proprietary Therapeutic Platform: NurOwn
    • 6.5.2 NurOwn Has Progressed to Phase 2
    • 6.5.3 BrainStorm Outlook in Summary: Financial Support and Manufacturing Optimisation Should Help Develop a Promising Therapy

7. Qualitative Analysis of the Stem Cell Technologies Market, 2016-2026

  • 7.1 SWOT Analysis of the Stem Cell Technologies Market
  • 7.2 Strengths
    • 7.2.1 Recent Approvals of Stem Cell Therapies
    • 7.2.2 Relaxation of Regulatory Barriers
    • 7.2.3 Huge Number of Ongoing Clinical Trials - Should Lead to a Barrage of Approvals over the Coming Years
    • 7.2.4 HSCT is Already an Established Procedure
  • 7.3 Weaknesses
    • 7.3.1 Phase 3 Trials Comprise Only a Small Fraction of Present Studies
    • 7.3.2 Regulatory and Reimbursement Concerns
    • 7.3.3 Uncertain Mechanism of Action in Stem Cell Therapies
  • 7.4 Opportunities
    • 7.4.1 Unmet Clinical Needs
    • 7.4.2 Interactions with Related Technologies
    • 7.4.3 Non-Therapeutic Uses: Cord Blood Banking and Cell-Based Assays
  • 7.5 Threats
    • 7.5.1 Financial Risks
    • 7.5.2 Pipeline Failure
    • 7.5.3 Long-term Safety Concerns
  • 7.6 STEP Analysis of the Stem Cell Technologies Market
  • 7.7 Social Factors
    • 7.7.1 Increasing Burden of Disease
    • 7.7.2 Biological Insurance through Stem Cell Banking
    • 7.7.3 Stem Cell Tourism: Opportunities and Threats to the Market
    • 7.7.4 The Overall Pharmaceutical Market Trend Towards Specialised Treatments Will Support Stem Cell Therapy Progress
    • 7.7.5 Trends Towards Emerging Markets and Partnerships Lead to More Complex Business Models
  • 7.8 Technological Factors
    • 7.8.1 Increasing Research Output
    • 7.8.2 IPSC Breakthroughs
    • 7.8.3 Greater Understanding of Stem Cell Differentiation
    • 7.8.4 Biomaterials, Bioprinting, and Other Developments
    • 7.8.5 CRISPR: A Breakthrough in Genome Editing
    • 7.8.6 Technology Will Drive a Trend Towards Collaboration to Access Novel Platforms
  • 7.9 Economic Factors
    • 7.9.1 Grey Market for Stem Cell Therapies
    • 7.9.2 Broad Changes in Healthcare Markets
    • 7.9.3 New Business Models Need to Be Developed
    • 7.9.4 Shift to the Emerging Marketplace
  • 7.10 Political Factors
    • 7.10.1 Controversies and Ethical Objections over Embryonic Stem Cell Research
    • 7.10.2 Strong Support from Some Governments
    • 7.10.3 Pressure to Deregulate the Stem Cell Therapies Market
    • 7.10.4 Restrictive Governmental Policies Due to Economic Recovery Strategies

8. Research Interviews

  • 8.1 Interview with Dr Silviu Itescu, MBBS, FRACP, CEO and Managing Director, Mesoblast Ltd, (ASX:MSB; Nasdaq:MESO), Australia
    • 8.1.1 Mesoblast: An Overview
    • 8.1.2 A Leader in the Stem Cell Technologies Market
    • 8.1.3 Mesoblast's Most Advanced Stem Cell Product
    • 8.1.4 Mesoblast's Biggest Strengths
    • 8.1.5 Challenges of the Stem Cell Technologies Market
    • 8.1.6 Future Areas of Focus in the Stem Cell Technology Market
    • 8.1.7 Comparing The Global Stem Cell Technology Market
  • 8.2 Interview with Dr Yael Margolin, PhD, President and CEO, Gamida Cell
    • 8.2.1 An Overview of Gamida Cell and Stem Cells Transplantation
    • 8.2.2 The Advantages of Gamida Cell's Leading Product
    • 8.2.3 Expanding on Gamida Cell's Stem Cell Product Portfolio
    • 8.2.4 Dealing With the Difficulties of Bringing a Stem Cell Product to Market
    • 8.2.5 Important Trends and Areas to Focus on in Bringing a Stem Cell Product Through Development
    • 8.2.6 Gamida Cell's Biggest Strength
    • 8.2.7 NiCord's Clinical Development
    • 8.2.8 Future Aims in the Stem Cell Technology Market

9. Conclusions

  • 9.1 The US Leads the Field for Stem Cell Research
  • 9.2 Market Remains Under Capitalised and Investment and Partnering is Essential
  • 9.3 The Industry Continues to Innovate New Discoveries
  • 9.4 Industry has Many Barriers to Overcome
  • 9.5 Competition Will Increase from 2016 to 2026
  • 9.6 The Future of the Stem Cells Technologies Market

List of Tables

  • Table 2.1 Overall World Stem Cell Technology and Applications Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2020
  • Table 2.2 Overall World Stem Cell Technology and Applications Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 2.3 Drivers and Restraints for the Stem Cell Technology and Applications Market, 2016-2026
  • Table 3.1 Osiris Therapeutics Overview, 2016
  • Table 3.2 Osiris Therapeutics: Stem Cell Revenue Forecast: Revenue ($m), Annual Growth (%), CAGR (%), 2015-2026
  • Table 3.3 Caladrius Biosciences Overview, 2016
  • Table 3.4 Caladrius Biosciences Revenue Breakdown: Revenue ($m), 2012-2015
  • Table 3.5 Orthofix Overview, 2016
  • Table 3.6 Orthofix: Trinity Elite and Trinity Evolution Revenue Forecast: Revenue ($m), Annual Growth (%), CAGR (%), 2015-2026
  • Table 3.7 NuVasive Overview, 2016
  • Table 3.8 NuVasive: Osteocel Plus Forecast: Revenue ($m), Annual Growth (%), CAGR (%), 2015-2026
  • Table 3.9 AlloSource Overview, 2016
  • Table 3.10 RTI Surgical Overview, 2016
  • Table 3.11 Vericel Corporation Overview, 2016
  • Table 3.12 Selected Advantages of Ixmyelocel-T Therapy, 2016
  • Table 3.13 Ixmyelocel-T Indications Under Investigation, 2016
  • Table 3.14 Vericel Corporation Revenues ($m), 2011-2014
  • Table 3.15 Vericel Corporation Q2 and Q3 Revenues ($m), Annual Growth (%), 2014-2015
  • Table 3.16 U.S. Stem Cell Inc Overview, 2016
  • Table 3.17 U.S. Stem Cell Inc, Revenues ($m), 2011-2015
  • Table 3.18 Neuralstem Overview, 2016
  • Table 3.19 Neuralstem Revenues ($m), 2011-2014
  • Table 3.20 Astellas/Ocata Therapeutics Overview, 2016
  • Table 3.21 Ocata Therapeutics Revenue ($m), 2011-2014
  • Table 3.22 Athersys Overview, 2016
  • Table 3.23 Athersys Revenue Breakdown ($m), 2012-2014
  • Table 3.24 FDA-Approved Cord Blood-Derived Stem Cell Products for HSCT, 2015
  • Table 4.1 Mesoblast Ltd Overview, 2016
  • Table 4.2 Mesoblast Partnerships, 2016
  • Table 4.3 Leading Products in Development at Mesoblast, 2016
  • Table 4.4 MSC-100-IV Forecast, Revenue ($m), Annual Growth Rate (%), CAGR (%), 2015-2026
  • Table 4.5 Mesoblast Revenue Breakdown ($m), 2012-2015
  • Table 4.6 Reliance Life Sciences Overview, 2016
  • Table 4.7 CardioRel Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2015-2026
  • Table 4.8 ReliCord® Programmes, 2016
  • Table 4.9 Anterogen Overview, 2016
  • Table 4.10 Anterogen Stem Cell Pipeline, 2016
  • Table 4.11 Pharmicell Overview, 2016
  • Table 4.12 Hearticellgram-AMI Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2026
  • Table 4.13 MEDIPOST Overview, 2016
  • Table 4.14 Cartistem Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2026
  • Table 4.15 Stempeutics Overview, 2016
  • Table 5.1 TiGenix Overview, 2016
  • Table 5.2 Celyad Overview, 2016
  • Table 5.3 Apceth Overview, 2016
  • Table 5.4 ReNeuron Overview, 2016
  • Table 5.5 ReNeuron Revenue Breakdown ($m), 2012-2015
  • Table 6.1 Gamida Cell Overview, 2016
  • Table 6.2 Gamida Cell Investors, 2016
  • Table 6.3 Cell Cure Neurosciences Overview, 2016
  • Table 6.4 Cell Cure Neurosciences Investors, 2016
  • Table 6.5 Pluristem Therapeutics Overview, 2016
  • Table 6.6 Pluristem Therapeutics Revenues ($m), 2012-2015
  • Table 6.7 BrainStorm Cell Therapeutics, 2016
  • Table 7.1 World Age 65+ Population Forecast: Population (m), AGR (%), CAGR (%), 2015-2026

List of Figures

  • Figure 1.1 Global Stem Cell Technology Market Segmentation Overview, 2016
  • Figure 2.1 Global Stem Cell Technology and Applications Market Forecast: Revenue ($m), 2015-2026
  • Figure 3.1 Osiris Therapeutics: Stem Cell Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 3.2 Caladrius Biosciences Revenue Breakdown: Revenue ($m), 2012-2015
  • Figure 3.3 Orthofix: Trinity Elite and Trinity Evolution Forecast: Revenue ($m), 2015-2026
  • Figure 3.4 NuVasive: Osteocel Forecast: Revenue ($m), 2015-2026
  • Figure 3.5 Vericel Corporation Revenue ($m), 2011-2013
  • Figure 3.6 Vericel Corporation Q2 and Q3 Revenues ($m), 2014-2015
  • Figure 3.7 U.S. Stem Cell Inc, Revenues ($m), 2011-2015
  • Figure 3.8 Neuralstem Revenue ($m), 2011-2014
  • Figure 3.9 Ocata Therapeutics Revenue ($m), 2011-2014
  • Figure 3.10 Athersys Revenue Breakdown ($m), 2012-2014
  • Figure 4.1 MSC-100-IV Forecast, Revenue ($m), 2015-2026
  • Figure 4.2 Mesoblast Revenue Breakdown ($m), 2012-2015
  • Figure 4.3 CardioRel Forecast: Revenue ($m), 2015-2026
  • Figure 4.4 Hearticellgram-AMI Forecast: Revenue ($m), 2015-2026
  • Figure 4.5 Cartistem Forecast: Revenue ($m), 2015-2026
  • Figure 5.1 ReNeuron Revenue Breakdown, 2012-2015
  • Figure 6.1 Pluristem Therapeutics Revenues ($m), 2012-2015
  • Figure 7.1 Stem Cell Technologies Market: Strengths and Weaknesses, 2016-2026
  • Figure 7.2 Stem Cell Technologies Market: Opportunities and Threats, 2016-2026
  • Figure 7.3 Stem Cell Technologies Market: STEP Analysis, 2016-2026
  • Figure 7.4 World Age 65+ Forecast: Population (m), 2015-2026
  • Figure 9.1 Nationalities of the Companies Profiled in this Report: Distribution

Companies Listed

  • Aastrom Biosciences (now called Vericel Corporation)
  • Advanced Cell Technology (now called Ocata Therapeutics)
  • Alkems
  • Allergan
  • AlloSource
  • American Academy of Pediatrics
  • Amgen
  • Amorcyte
  • Anterogen
  • Apceth
  • Arthrex
  • Astellas
  • AstraZeneca
  • Athelos
  • Athersys
  • Auriga Ventures
  • BaYi Brain Hospital
  • Benitec Biopharma
  • Berlin-Brandenburg Center for Regenerative Therapy
  • Biogenea-Cellgenea
  • Bioheart
  • BioTime
  • Blackstone Medical
  • Bloodworks Northwest
  • BrainStorm Cell Therapeutics
  • Bristol-Myers Squibb
  • Caladrius Biosciences
  • California Institute of Regenerative Medicine (CIRM)
  • California Stem Cell Inc
  • Cardio3 BioSciences
  • Carolinas Cord Blood Bank (CCBB)
  • Casey Eye Institute
  • Catapult Cell Therapy
  • Celgene
  • Cell Cure Neurosciences
  • Cellectis
  • Cellerix
  • CELLTREE
  • Celyad
  • Cephalon
  • CFDA (China Food and Drug Administration)
  • CHA Bio & Diostech
  • Cha General Hospital
  • Charité - University Medicine Berlin
  • China's National Health and Family Planning Commission (NHFPC)
  • Chinese Academy of Sciences
  • Chinese Ministry of Health
  • Chinese Ministry of Science and Technology
  • Chugai Pharmaceutical
  • Cipla
  • CJ CheilJedang
  • Clal Biotechnologies Industries
  • Clinicaltrials.gov
  • ClinImmune Labs
  • Columbia University
  • Committee for Advanced Therapies (CAT)
  • Committee for Medicinal Products for Human Use (CHMP)
  • Corniche Group
  • CRISPR Therapeutics
  • CSCR (Centre for Stem Cell Research)
  • Cynata Therapeutics
  • Denali Ventures
  • Dong-A Pharmaceuticals Co.
  • Duke University School of Medicine
  • Editas Medicine
  • Elbit Imaging
  • Elbit Medical Technologies
  • Eli Lilly
  • Elsevier
  • European Commission
  • European Medicines Agency (EMA)
  • Forbion Capital Partners
  • Fukushima Global Medical Science Center
  • Fukushima Medical University
  • Gamida Cell
  • Genetrix
  • Geron
  • Gladstone Institute
  • Hadasit Bio-Holdings, Ltd (HBL)
  • Hadassah University Hospital
  • Harvard Medical School
  • Healios
  • Hebrew University of Jerusalem
  • Human Fertilisation and Embryology Authority (HFEA)
  • Human Stem Cells Institute
  • ICMR (Indian Council for Medical Research)
  • IC-SCRT (Institutional Committee for Stem Cell Research)
  • Indian Department of Biotechnology
  • Intellia Therapeutics
  • International Society for Stem Cell Research (ISSCR)
  • Invetech
  • ISCS (Israel Stem Cell Society)
  • Israel Healthcare Venture
  • Israel Stem Cell Society
  • Japanese Health Ministry
  • Japanese Institute of Biomedical Research
  • Japanese Ministry of Economy, Trade and Industry (METI)
  • Japanese NHI (National Health Insurance)
  • Japanese PMDA (Pharmaceutical and Medical Devices Agency)
  • JCR Pharmaceuticals
  • JingYuan Bio
  • Korean Food and Drug Administration (KFDA)
  • Korean Ministry of Food and Drug Safety (MFDS)
  • Korean Ministry of Health and Welfare
  • LifeCord
  • LifeSouth
  • Lincoln Park Capital Fund
  • Lonza
  • Mayo Clinic
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • MEDIPOST
  • Medisun International Limited
  • Medtronic
  • Merck Millipore
  • Mesoblast
  • Michigan State University
  • Monash University
  • Musculoskeletal Transplant Foundation (MTF)
  • NAC-SCRT (National Apex Committee for Stem Cell Research and Therapy)
  • National Institute of Health and Care Excellence (NICE)
  • Nature
  • NeoStem
  • Neuralstem
  • New York Blood Center
  • New York Heart Association
  • NHFPC (National Health and Family Planning Commission)
  • NHMRC (National Health and Medical Research Council)
  • Novartis
  • NuVasive
  • Ocata Therapeutics
  • OCS (Office of the Chief Scientist)
  • Octane Biotech Inc
  • Oregon Health and Science University
  • OrLife Bio
  • Orthofix
  • Osiris Therapeutics
  • Pharmicell
  • Phase III Medical Inc.
  • Pluristem Therapeutics
  • Progenitor Cell Therapy (PCT)
  • Puget Sound Blood Center
  • Ramot
  • Reliance Group
  • Reliance Life Sciences
  • ReNeuron
  • Roche
  • RTI Surgical
  • Sanofi
  • Schepens Eye Research Institute
  • Singapore National Eye Centre
  • Society for Neuroscience
  • Society for Stem Cell Research (ISSCR)
  • SSM Cardinal Glennon Children's Medical Center
  • St. Louis Cord Blood Bank
  • StemGen
  • Stempeutics
  • Stryker Corporation
  • Swedish Orphan Biovitrum AB (Sobi)
  • Tel Aviv University
  • Teva Pharmaceutical Industries
  • TGA (Therapeutic Goods Administration)
  • The Lancet
  • ThermoFisher
  • TiGenix
  • ToolGen
  • UK Department of Health and the Medical Research Council
  • UK Medicines and Healthcare Products Regulatory Agency (MHRA)
  • uniQure
  • United Nations Department of Economic and Social Affairs
  • United Therapeutics
  • University College London
  • University of Colorado Anschutz Medical Campus (AMC)
  • University of Colorado Cord Blood Bank
  • University of Kyoto
  • University of Melbourne
  • University of Wisconsin Alumni Research Foundation
  • US Congress
  • US Department of Defense (DOD)
  • US Federal Reserve
  • US Food and Drug Administration (FDA)
  • US National Academy of Sciences
  • US National Institute of Health
  • US Patent and Trademark Office
  • U.S. Stem Cells Inc.
  • Vericel Corporation
  • Viacyte
  • Woodford Investment Management
  • Yonsei University
Back to Top